Search Results
Your search for ,WHo matches 20390 pages
Showing 11401 - 11450Combination Immunotherapy in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Overman et al, findings in the nivolumab (Opdivo) plus ipilimumab (Yervoy) cohort of the CheckMate-142 study indicate a high response rate and durable responses with the combination in previously treated patients with DNA mismatch...
ASCO and NCCN Provide Guidelines for Managing Immunotherapy Side Effects
Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into...
ALK Variant, Resistance, and Clinical Outcomes in ALK-Positive NSCLC
In a study reported in the Journal of Clinical Oncology, Lin et al found that specific ALK variants may be associated with the development of resistance mutations to ALK tyrosine kinase inhibitors (TKIs) in ALK-positive non–small cell lung cancer (NSCLC). Study Details The study involved...
2018 SURVIVORSHIP: Many Young Adult Cancer Survivors Forgo Follow-up Care After Cancer Treatment Ends
Despite survivorship guidelines from ASCO and other organizations regarding follow-up care after cancer treatment ends, follow-up care is generally lacking for adolescent and young adult (AYA) cancer survivors. Since AYA cancer survivors are at an increased risk for late effects from their cancer...
2018 SURVIVORSHIP: Therapeutic Sexual Aids Frequently Not Available for Cancer Survivors Who Need Them
Cancer care guidelines recommend that cancer survivors who experience sexual dysfunction after cancer treatment use therapeutic aids to help improve their sexual health. However, a new study of 25 leading cancer centers found that 87% of the centers reported having no sexual aids available on site...
2018 SURVIVORSHIP: Exercise Speeds Improvement in Arm Mobility After Surgery for Breast Cancer
New findings from a clinical trial of women with breast cancer suggest that guided exercise with a physical therapist after lymph node dissection helps women regain their range of arm motion more quickly. These findings will be presented by Paskett et al at the upcoming 2018 Cancer Survivorship...
2018 SURVIVORSHIP: Exercising During Chemotherapy for Breast or Colon Cancer Has Long-Term Benefits
A follow-up study to a randomized clinical trial reveals that exercising during adjuvant chemotherapy helps people engage in more physical activity years later. Four years later, people with breast or colon cancer who had participated in an 18-week exercise program while receiving chemotherapy...
2018 SURVIVORSHIP: Web-Based Interventions Help Adolescents Stay Physically Active After Cancer Treatment
Survivors of childhood cancer are at increased risk for obesity and metabolic syndrome, which can lead to other serious health conditions, including heart disease, stroke, and diabetes. However, engaging in regular physical activity may help remediate these health issues in young survivors. A...
Synchronous Distant and Locoregional Recurrence in Stage II and III Breast Cancer
In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Neuman et al found that synchronous distant recurrence was identified in 27% of women with stage II or III breast cancer experiencing locoregional recurrence. Study Details The study—an American...
2018 GU CANCERS SYMPOSIUM: Antiandrogenic Therapy in Nonmetastatic Castration-Resistant Prostate Cancer
Results from the phase III PROSPER trial in patients with nonmetastatic castration-resistant prostate cancer were presented by Hussain et al at the 2018 Genitourinary Cancers Symposium (Abstract 3). The results show that the use of enzalutamide (Xtandi) plus androgen-deprivation therapy (ADT)...
2018 GU CANCERS SYMPOSIUM: Early-Phase Trial of Glutaminase Inhibitor CB-839 in Combination With Cabozantinib or Everolimus in Renal Cell Carcinoma
Data on CB-839, a first-in-class glutaminase inhibitor, will be presented by Tannir et al at the 2018 Genitourinary Cancers Symposium in San Francisco (Abstract 603). The data are from the CX-839-001 study, which includes cohorts evaluating the safety, efficacy and recommended phase II dose of ...
2018 GU CANCERS SYMPOSIUM: Combination Therapy Shows Antitumor Activity in Advanced Renal Cell Carcinoma
Combining the antiangiogenic agent axitinib (Inlyta) with the immunotherapy pembrolizumab (Keytruda) was found to have promising antitumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer who had not been previously treated. The full...
FDA Approves Abiraterone Acetate in Combination With Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer
On February 7, 2018, the U.S. Food and Drug Administration (FDA) approved abiraterone acetate (Zytiga) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer. The FDA initially approved abiraterone acetate with prednisone in 2011 for patients with...
Gateway for Cancer Research Renews Commitment to Young Investigators
Gateway for Cancer Research has renewed and expanded its support for the Conquer Cancer Foundation Young Investigator Award Program. The organization will underwrite the Gateway for Cancer Research Young Investigator Award (YIA) for each of the next 3 years to enable promising physician-scientists...
CancerLinQ LLC Partners With the National Society of Genetic Counselors
CancerLinQ LLC and the National Society of Genetic Counselors (NSGC), the professional society for genetic counselors, announced that they have entered into a strategic alliance. With the collaboration, NSGC leaders and members will provide expertise to CancerLinQ®, ASCO’s health information...
ASCO/CCO Focused Guideline Update on Role of Bone-Modifying Agents in Metastatic Breast Cancer
AS REPORTED BY Catherine Van Poznak, MD, FASCO, of the University of Michigan, Ann Arbor, and colleagues in the Journal of Clinical Oncology, ASCO and Cancer Care Ontario (CCO) have collaborated in providing a focused update for the ASCO clinical practice guideline on the role of bone-modifying...
Avelumab in Advanced Urothelial Carcinoma: Further Study Needed to Clarify its Role
AS REVIEWED in this issue of The ASCO Post, Patel and colleagues have presented data from the phase I JAVELIN study evaluating avelumab (Bavencio) in platinum-refractory patients with advanced urothelial carcinoma.1 The drug is active with durable responses when compared with historical...
Prosigna Score and 10-Year Distant Recurrence in Women Receiving Endocrine Therapy for Early Breast Cancer
In a Danish study reported in the Journal of Clinical Oncology, Lænkholm and colleagues found that the PAM50-based Prosigna risk of recurrence score could identify lower risk of 10-year distant recurrence in subgroups of postmenopausal women who received 5 years of endocrine therapy alone for ...
Differentiating Cancerous Prostate Tissue From Benign Tissue
Using nuclear medicine, German researchers may have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in findings published by Rahbar et al in The Journal of Nuclear Medicine. These new findings demonstrate that...
EXPERT POINT OF VIEW: Eric P. Winer, MD, FASCO; Heikki Joensuu, MD; and Julie Gralow, MD, FASCO
IN INTERVIEWS with The ASCO Post and in discussions held during the meeting, several breast cancer experts weighed in on the findings of GeparSepto and CALGB 40502. Eric P. Winer, MD, FASCO, Chief of the Division of Women’s Cancers and the Thompson Senior Investigator in Breast Cancer Research at ...
Updates of Key Studies Differ on Relative Benefit of Nab-Paclitaxel in Breast Cancer
TWO IMPORTANT STUDIES, both updates of earlier findings and presented at the 2017 San Antonio Breast Cancer Symposium, provided different findings as to the relative benefit of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane), vs solvent-based paclitaxel in breast cancer. “The two studies...
EXPERT POINT OF VIEW: Julie Gralow, MD, FASCO
JULIE GRALOW, MD, FASCO, Director of Breast Medical Oncology for the Seattle Cancer Care Alliance and Professor of Medical Oncology at the University of Washington School of Medicine, commented on the findings of the SUCCESS A trial in an interview with The ASCO Post. The Oxford meta-analysis...
EXPERT POINT OF VIEW: C. Kent Osborne, MD, and Joseph Sparano, MD
“ONCOLOGISTS WANT to find drugs that will delay the use of chemotherapy, and cyclin-dependent kinase (CDK) 4/6 inhibitors provide that. These agents work better than chemotherapy and with less toxicity,” said press conference moderator C. Kent Osborne, MD, Director of the Duncan Cancer Center at...
CDK 4/6 Inhibitors May Be Effective but More Toxic in Older Women
OLDER WOMEN with breast cancer derive benefit from treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors as part of initial endocrine-based therapy for hormone receptor–positive, HER2-negative, metastatic breast cancer, according to a retrospective pooled subgroup analysis of women aged 70 or ...
Novel Agent Appears Active in Advanced or Aggressive Systemic Mastocytosis
THE INVESTIGATIONAL agent BLU-285 (avapritinib) has shown significant activity in patients with advanced or aggressive forms of systemic mastocytosis, a rare blood disorder that originates in mast cells, according to the findings of a phase I trial reported at the 2017 American Society of...
Daratumumab Shows Efficacy in Amyloid Light-Chain Amyloidosis
DARATUMUMAB (DARZALEX) may be an effective treatment for systemic amyloid light-chain (AL) amyloidosis, according to phase II studies reported at the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition.1,2 While the cohorts were small and the arms uncontrolled, the findings...
Superior Progression-Free Survival With First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in NSCLC With High Tumor Mutation Burden
The ongoing phase III CheckMate-227 study met its coprimary endpoint of progression-free survival with a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) vs chemotherapy in patients with first-line advanced non–small cell lung cancer (NSCLC) whose tumors have a high (≥ 10...
For Patients Treated for Myeloma, Antibiotic Prophylaxis May Reduce Infections and Deaths
IN PATIENTS undergoing treatment of multiple myeloma, the prophylactic use of levofloxacin significantly reduced febrile episodes and deaths, without increasing healthcare-associated infections or carriage of key nosocomial pathogens, in a large multicenter study from the United Kingdom.1 The...
Possible Link Between Drinking Hot Tea and Increased Chance of Esophageal Cancer in High-Risk Individuals
Esophageal cancer is the eighth most common cancer worldwide, with an estimated 456,000 new cases in 2012, and the sixth most common cause of death from cancer with an estimated 400,000 deaths, according to data from GLOBOCAN, which provides statistics on the incidence and mortality of cancer...
ASCO Clinical Practice Guideline: Treatment of Malignant Pleural Mesothelioma
As reported by Hedy L. Kindler, MD, of the University of Chicago, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on treatment of malignant pleural mesothelioma. The guideline was informed by a systematic literature search and expert panel review ...
Long-Term Results of PET-Adapted Therapy for Advanced Hodgkin Lymphoma
As reported by Gallamini et al in the Journal of Clinical Oncology, the Italian GITIL/FIL HD 0607 trial has shown good long-term outcomes with the switch from ABVD (doxorubicin, vinblastine, vincristine, and dacarbazine) to escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide,...
Patient Refusal of Esophagectomy and Long-Term Survival
Patients with esophageal cancer who refuse surgery when it is recommended are less likely to survive long term than similar groups of patients who undergo an operation, according to research presented by Ghaly et al at the 54th Annual Meeting of The Society of Thoracic Surgeons (P78). ...
Scientific Statement From the American Heart Association Examines Intersection of Breast Cancer and Cardiovascular Disease
Patients with breast cancer may be at an increased risk of cardiovascular diseases, including heart failure, and may benefit from a treatment approach that weighs the benefits of specific therapies against potential damage to the heart, according to a new scientific statement from the American...
NCCN Awards Nine Grants for Quality Improvement in Breast Cancer Care
THE NATIONAL COMPREHENSIVE Cancer Network® (NCCN®) Oncology Research Program in collaboration with Pfizer Global Medical Grants announced they have awarded funding to nine projects that use clinical care pathways to implement quality improvement initiatives along the continuum of care for...
2018 GU CANCERS SYMPOSIUM: Chemotherapy Added to Hormone Therapy for Prostate Cancer Improves Quality of Life
A new analysis of the ongoing STAMPEDE clinical trial found that adding docetaxel to hormone therapy for advanced prostate cancer improves quality of life and lowers the need for subsequent therapy. Docetaxel was also found to be cost-effective. These findings will be presented by James et al at...
2018 GU CANCERS SYMPOSIUM: Adding Immunotherapy to Standard Treatment Slows Growth of Advanced Kidney Cancer—With Fewer Side Effects
In a phase III clinical trial of patients with previously untreated metastatic renal cell cancer combining the immunotherapy atezolizumab (Tecentriq) with the targeted therapy bevacizumab (Avastin) delayed cancer growth by about 3 months longer than sunitinib, another targeted therapy. The benefit...
2018 GU CANCERS SYMPOSIUM: New Model Predicts Survival for People With Bladder Cancer Receiving Immunotherapy
Researchers have developed a model to predict overall survival for people with advanced urothelial cancers treated with the immune checkpoint inhibitor atezolizumab (Tecentriq). The model, which is based on six clinical factors, may help inform treatment decisions for use of atezolizumab in these...
2018 GU CANCERS SYMPOSIUM: Apalutamide Delays Prostate Cancer Metastases by More Than 2 Years
Findings from the phase III placebo-controlled SPARTAN trial suggest that apalutamide is an effective treatment for men with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease and for whom no approved treatments exist. Men who received...
EXPERT POINT OF VIEW: Stephen Leong, MD
STEPHEN LEONG, MD, of the University of Colorado Comprehensive Cancer Center, Aurora, discussed the RAINFALL findings at the symposium, commenting, “The study did meet its primary endpoint of progression-free survival; however, it was disappointing not to see a benefit in overall survival or...
Ramucirumab/Chemotherapy in Gastric Cancer: ‘Positive’ Trial but Insufficient Benefit
BASED ON EFFICACY seen in the second-line setting for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma, ramucirumab (Cyramza) was evaluated as first-line therapy in the international phase III RAINFALL trial. Although the study met its primary endpoint, with a 25%...
Bone-Modifying Agents in Metastatic Breast Cancer: Time to De-escalate Dosing Intervals
AS REVIEWED in this issue of The ASCO Post, ASCO and Cancer Care Ontario (CCO) have issued an updated guideline on the role of bone-modifying agents in metastatic breast cancer.1 The updated guideline supports a change in clinical practice for our patients with breast cancer and bone metastasis....
EXPERT POINT OF VIEW: Zsofia Kinga Stadler, MD
DISCUSSANT ZSOFIA KINGA STADLER, MD, of Memorial Sloan Kettering Cancer Center, found the nivolumab (Opdivo)/ipilimumab (Yervoy) combination results very encouraging but was also impressed with the monotherapy arm. Both approaches are significant advances in treatment, she said. “The treatment of ...
Nivolumab Plus Ipilimumab Improves Outcomes in Metastatic Colorectal Cancer
IN THE FIRST REPORT of the full cohort of CheckMate-142, nivolumab (Opdivo) plus ipilimumab (Yervoy) led to a 1-year overall survival rate of 85% in previously treated patients with metastatic colorectal cancer who have DNA mismatch repair–deficient (dMMR) or microsatellite instability–high...
Howard S. Hochster, MD, Joins Rutgers Cancer Institute
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health welcome Howard S. Hochster, MD, an internationally recognized leader in the development of cancer clinical trials, gastrointestinal oncology, and early-phase cancer drugs. In January, Dr. Hochster assumed the role of Associate Director...
Addition of EGFR-Targeting Vaccine to Temozolomide in EGFRvIII-Expressing Glioblastoma
The phase III ACT IV study has shown no survival benefit of adding rindopepimut, a vaccine targeting the epidermal growth factor receptor (EGFR) deletion mutation EGFRvIII, to temozolomide in patients with newly diagnosed EGFRvIII-positive glioblastoma. These findings were reported in The Lancet...
Steep Decline in Chemotherapy Use for Early-Stage Breast Cancer
The use of chemotherapy to treat women with early-stage breast cancer “declined markedly over time,” according to analysis of data from 2,926 women between the ages of 20 and 79. The trends documented “are remarkable for their steepness of decline, independent of clinical factors and despite no...
I’m Not a Victim of Cancer
What I thought after feeling a large, hard lump—similar to the feel of a granola bar—in my left breast was that I probably pulled a muscle while playing with my two young children, ages 7 and 5. Cancer never entered my mind until I asked my husband to feel the lump, and he immediately said, with...
The Toxicity of Time
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Daratumumab in Previously Treated Multiple Myeloma
On June 16, 2017, daratumumab -(Darzalex) was approved for use in combination with pomalidomide (Pomalyst) and dexamethasone for treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide (Revlimid) and a proteasome inhibitor.1,2 Supporting...
Pembrolizumab in MSI-H or dMMR Solid Tumors: ‘First Tissue/Site-Agnostic’ Approval by FDA
On May 23, 2017, pembrolizumab (Keytruda) was granted accelerated approval for treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors progressing following prior treatment and who have no...
